INBRIJA (levodopa inhalation powder), 42 mg capsules

Role of as-needed therapies transcript

(TITLE SLIDE)

[Purple and gold sail and INBRIJA® logo appear]

(ON-SCREEN TEXT)

PRACTICAL CONSIDERATIONS
for Treating Parkinson's Disease Symptoms When They Return:
Expert Perspectives
INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa
Selected Important Safety Information

See additional Important Safety Information later in this video.

ROLE OF AS-NEEDED THERAPIES
A Discussion With:
Peter A. LeWitt, MD | Fernando Pagan, MD | Salima Brillman, MD

(DESCRIPTION)

[Dr. LeWitt talking to camera]

(ON SCREEN TEXT)

PETER A. LEWITT, MD
Director, Parkinson's Disease and Movement Disorders Program at Henry Ford Hospital
Professor of Neurology at Wayne State University School of Medicine

(DR. LEWITT)

And I'm going to turn to Fernando to discuss the role for therapies used as-needed in Parkinson's disease.

(DESCRIPTION)

[Dr. Pagan talking to camera]

(ON SCREEN TEXT)

FERNANDO PAGAN, MD
Professor and Vice Chairman,
Department of Neurology at MedStar Georgetown University Hospital

(DR. PAGAN)

So, Dr. LeWitt, I think one of the interesting things that we've seen a shift in paradigm of how we're approaching Parkinson's is that we've usually used maintenance therapies to treat the motor symptoms of Parkinson's. Again, levodopa is the main maintenance therapy that we have to treat the motor symptoms of Parkinson's, and along the way, when we start to see more OFF periods reemerge, we tend to use a lot of adjunctive therapies and when we see the return of symptoms we do have as-needed therapies. And INBRIJA is an excellent example of this as-needed therapy to use when you see the return of symptoms.

(ON SCREEN TEXT)

1 dose of INBRIJA (84mg) is administered in two 42-mg capsules. No more than 1 dose can be administered per period of symptom return, and patients may take up to a maximum of 5 doses per day as needed.

(DESCRIPTION)

[Slide appears with purple background]

(ON SCREEN TEXT)

WHY SHOULD A PHYSICIAN USE A THERAPY LIKE INBRIJA versus adjusting the patient’s baseline medications?

(DESCRIPTION)

[Dr. Brillman talking to camera]

(ON SCREEN TEXT)

SALIMA BRILLMAN, MD
Parkinson's Disease and Movement Disorders Center of Silicon Valley

(DR. BRILLMAN)

They're not mutually exclusive, of course, and one can do both. In terms of the utilization of INBRIJA and adjusting the baseline medications, we have to remember that people can have partial ONs, they can have failed ONs, that no matter how one adjusts their oral medications, they still may have failure of ONs. So these kinds of OFF periods can be benefited by the utilization of INBRIJA.

(DESCRIPTION)

[Slide appears with purple background]

(ON SCREEN TEXT with VOICEOVER)
(INBRIJA LOGO)

Indication
INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) treated with carbidopa/levodopa.

Important Safety Information

Please see the Full Prescribing Information at www.INBRIJAFullPI.com

(DESCRIPTION)

[Slide appears with purple background]

(ON SCREEN TEXT)
(INBRIJA LOGO)
(ACORDA LOGO)

ACORDA THERAPEUTICS, the stylized ACORDA THERAPEUTICS logo, INBRIJA and the INBRIJA logo are all trademarks of Acorda Therapeutics, Inc.© 2021 Acorda Therapeutics, Inc. All rights reserved.

02/2021 INB9263

[END OF TRANSCRIPT]

View the referenced video

06/21 INB10407